StockNews.com Upgrades Ascendis Pharma A/S (NASDAQ:ASND) to Hold

Ascendis Pharma A/S (NASDAQ:ASND) was upgraded by research analysts at StockNews.com from a “sell” rating to a “hold” rating in a research note issued on Thursday.

Other analysts have also recently issued research reports about the stock. Cantor Fitzgerald dropped their price objective on shares of Ascendis Pharma A/S from $173.00 to $170.00 and set an “overweight” rating on the stock in a report on Wednesday. Stifel Nicolaus assumed coverage on Ascendis Pharma A/S in a report on Friday, May 31st. They set a “buy” rating and a $200.00 price target on the stock. Evercore ISI raised Ascendis Pharma A/S to a “strong-buy” rating in a report on Monday, August 26th. Oppenheimer raised Ascendis Pharma A/S from a “market perform” rating to an “outperform” rating and set a $180.00 target price on the stock in a research note on Thursday. Finally, TD Cowen reduced their price target on Ascendis Pharma A/S from $175.00 to $157.00 and set a “buy” rating for the company in a research report on Wednesday. Two investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $187.08.

Ascendis Pharma A/S Price Performance

Shares of ASND opened at $119.15 on Thursday. Ascendis Pharma A/S has a 12 month low of $85.29 and a 12 month high of $161.00. The stock has a fifty day moving average price of $134.38 and a 200 day moving average price of $138.20. The company has a market cap of $6.94 billion, a P/E ratio of -12.40 and a beta of 0.63.

Institutional Investors Weigh In On Ascendis Pharma A/S

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Avoro Capital Advisors LLC boosted its position in shares of Ascendis Pharma A/S by 5.8% in the 2nd quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company’s stock valued at $572,341,000 after purchasing an additional 229,995 shares during the period. Westfield Capital Management Co. LP boosted its holdings in shares of Ascendis Pharma A/S by 1.1% in the first quarter. Westfield Capital Management Co. LP now owns 4,075,214 shares of the biotechnology company’s stock worth $616,050,000 after buying an additional 44,580 shares during the period. Capital International Investors increased its position in shares of Ascendis Pharma A/S by 0.5% in the first quarter. Capital International Investors now owns 2,191,312 shares of the biotechnology company’s stock worth $331,261,000 after acquiring an additional 10,044 shares in the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of Ascendis Pharma A/S by 23.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company’s stock worth $269,374,000 after acquiring an additional 336,976 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA raised its holdings in shares of Ascendis Pharma A/S by 5.8% during the second quarter. Massachusetts Financial Services Co. MA now owns 1,711,015 shares of the biotechnology company’s stock valued at $233,348,000 after acquiring an additional 93,185 shares during the period.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.